title: Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages.
abstract: Linomide is a potent immunomodulator that has been shown to inhibit autoimmunity in several animal models of autoimmune disease, including experimental autoimmune encephalomyelitis (EAE). Linomide's mechanism of action is unknown, however, it has been suggested to modulate the function of antigen presenting cells (APC) and that this may account for the inhibition of autoimmune disease. In this study we have been able to show that Linomide treatment of SJL/N mice upregulates the cell surface expression of several activation markers on macrophages and B cells. Thus, we found the following markers, expressed as a % of control, to be significantly upregulated following Linomide treatment; MHC class II (260%), Ly-6A/E (520%), CD11a (280%), CD54 (190%) and CD80 (200%) on macrophages and Ly-6A/E (250%) and CD11a (150%) on B cells. The duration and dosage of Linomide required to obtain these effects is similar to those required for EAE inhibition. Several Linomide analogues were made by the introduction of structural modifications into the Linomide molecule, resulting in a number of compounds with varying effects on EAE. We found a linear relationship between the compound's ability to inhibit EAE and its ability to upregulate MHC class II on macrophages (p<0.001), such that compounds which were able to inhibit EAE also upregulated MHC class II expression, whereas those that did not inhibit EAE were unable to do so. These results suggest that drug-mediated activation of distinct APC functions may be protective in autoimmunity.
authors.affiliation: Active Biotech Research AB, Lund, Sweden.
authors.forename: E
authors.initials: E
authors.lastname: Dahlén
authors.forename: M
authors.initials: M
authors.lastname: Andersson
authors.forename: K
authors.initials: K
authors.lastname: Dawe
authors.forename: A C
authors.initials: AC
authors.lastname: Tellander
authors.forename: C
authors.initials: C
authors.lastname: Brunmark
authors.forename: A
authors.initials: A
authors.lastname: Björk
authors.forename: G
authors.initials: G
authors.lastname: Hedlund
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D000943:Antigens, Differentiation; D000944:Antigens, Differentiation, B-Lymphocyte; D000950:Antigens, Ly; D001402:B-Lymphocytes / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy*; D005260:Female; D005802:Genes, MHC Class II; D006912:Hydroxyquinolines / Q000627:therapeutic use*; D008262:Macrophage Activation; D017737:Macrophages, Peritoneal / Q000187:drug effects*; D008565:Membrane Proteins; D051379:Mice; D008810:Mice, Inbred C57BL; D016688:Mice, Inbred NOD; D015854:Up-Regulation
chemical_list: D000276:Adjuvants, Immunologic; D000943:Antigens, Differentiation; D000944:Antigens, Differentiation, B-Lymphocyte; D000950:Antigens, Ly; D006912:Hydroxyquinolines; C074650:Ly6a protein, mouse; D008565:Membrane Proteins; C045282:roquinimex